CVRx, Inc. (CVRX)
| Market Cap | 14.27M -94.0% |
| Revenue (ttm) | 60.33M +7.8% |
| Net Income | -53.26M |
| EPS | -2.00 |
| Shares Out | 28.49M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 520,660 |
| Open | 0.5252 |
| Previous Close | 0.5329 |
| Day's Range | 0.4972 - 0.5690 |
| 52-Week Range | 0.4972 - 10.2800 |
| Beta | 0.76 |
| Analysts | Hold |
| Price Target | 1.65 (+229.34%) |
| Earnings Date | Nov 5, 2026 |
About CVRX
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its... [Read more]
Financial Performance
In 2025, CVRx, Inc.'s revenue was $56.65 million, an increase of 10.45% compared to the previous year's $51.29 million. Losses were -$53.31 million, -11.10% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for CVRX stock is "Hold." The 12-month stock price target is $1.65, which is an increase of 229.34% from the latest price.
News
What Does CVRx, Inc.'s 59.76% Stock Drop Mean for Investors? The Law Offices of Howard G.
Suit alleges CVRx, Inc. failed to disclose key facts to investors from July 25, 2023 through August 6, 2026; lead plaintiff deadline is January 8, 2027 BENSALEM TOWNSHIP, Pa., Nov. 19, 2026 /PRNewswir...
CVRx, Inc. Transcript: Jefferies Global Healthcare Conference
Barostim targets a large heart-failure market, with trial and clinical evidence supporting its potential to improve symptoms. Sales execution, specialist staffing and payer approvals remain key growth constraints, while coverage and referral-building efforts advance.
What Should CVRx, Inc. Investors Know After 59.76% Stock Drop? The Law Offices of Frank R.
Lawsuit alleges CVRx, Inc. made misleading statements to investors from July 25, 2023 to August 6, 2026; lead plaintiff motions are due January 8, 2027 LOS ANGELES, Nov. 18, 2026 /PRNewswire/ -- The L...
CVRx to Participate at the Piper Sandler 38th Annual Healthcare Conference
MINNEAPOLIS, Nov. 17, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of January 8, 2027 in CVRx, Inc. Lawsuit - CVRX
CVRx's SEC filings framed inappropriate promotion and government investigations as possibilities, while the lawsuit alleges improper Barostim marketing and kickback practices were already contributing...
CVRx, Inc. Transcript: Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum
The largest Medicare Advantage payer’s approval rate fell to 12% by end-Q3, while health-system payment concerns and specialist turnover add adoption friction. Management sees execution across all nine regions as the route back to double-digit growth and is investing in clinical evidence and reimbursement appeals.
CVRx price target lowered to $1.25 from $4 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on CVRx (CVRX) to $1.25 from $4 and keeps a Hold rating on the shares. The firm notes the company reported Q3 results largely…
CVRx price target lowered to $1.50 from $3.50 at Lake Street
Lake Street lowered the firm’s price target on CVRx (CVRX) to $1.50 from $3.50 and keeps a Hold rating on the shares. The firm decreased its 2026 and 2027 revenue…
CVRx downgraded to Hold from Buy at Canaccord
Canaccord downgraded CVRx (CVRX) to Hold from Buy with a price target of $2, down from $5. Though Q3 revenue was roughly in line, CVRx cut FY26 guidance and noted…
CVRx price target lowered to $1.50 from $4 at Piper Sandler
Piper Sandler analyst Matt O’Brien lowered the firm’s price target on CVRx (CVRX) to $1.50 from $4 and keeps a Neutral rating on the shares. The firm notes the company…
CVRx downgraded to Market Perform from Outperform at William Blair
William Blair downgraded CVRx (CVRX) to Market Perform from Outperform without a price target following the Q3 report. The headwinds the company has been working through since last quarter have…
CVRx, Inc. Earnings Call Transcript: Q3 2026
Q3 revenue fell 6.1% YoY as payer delays, physician turnover and uneven sales execution pressured results. FY2026 revenue guidance was lowered, while clinical evidence, two payer policies and cost actions support the recovery effort.
CVRx, Inc. Earnings release: Q3 2026
CVRx, Inc. released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
CVRx, Inc. Quarterly report: Q3 2026
CVRx, Inc. has published its Q3 2026 quarterly earnings report on November 5, 2026.
CVRx Reports Third Quarter 2026 Financial and Operating Results
MINNEAPOLIS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...
CVRx to Participate in Upcoming Investor Conferences
MINNEAPOLIS, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...
CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026
MINNEAPOLIS, Oct. 22, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...
CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026
MINNEAPOLIS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for pa...
CVRx appoints John Landry as CFO
CVRx (CVRX) announced that John Landry has been appointed CFO, succeeding Jared Oasheim, whose resignation was previously announced. Landry will join the company on October 12, and assume the CFO…
CVRx Appoints John Landry as Chief Financial Officer
Landry Brings Two Decades of Medtech and Public Company Finance Experience Landry Brings Two Decades of Medtech and Public Company Finance Experience
CVRx Responds to Letter from Pointillist Family Office
MINNEAPOLIS, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...
CVRx announces Devoted Health Medicare Advantage coverage policy for Barostim
CVRx (CVRX) announced that Devoted Health has issued a Medicare Advantage coverage policy for Barostim therapy, effective July 17. Devoted Health, a national health insurance company with the eighth l...
Jorey Chernett urges CVRx board to commence formal sales process
Jorey Chernett, Founder of Pointillist Family Office and beneficial owner of more than 5.5% of the outstanding shares of CVRx (CVRX), delivered a letter to the CVRx Board of Directors…
Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer
Delivers Letter to the CVRx Board Highlighting Significant Value Proposition of Barostim to a Large Medical Device Company with Established Infrastructure to Capitalize on the Product's Market Positio...
CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy
MINNEAPOLIS, Aug. 24, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...